Overexpression of MiR‐29b‐3p Inhibits Atrial Remodeling in Rats by Targeting PDGF‐B Signaling Pathway

Figures

• 

  Figure 1. MiR-29b-3p expression levels and its stable binding with PDGF-B. (a) RT-PCR detects the expression of miR-29b-3p in atrial tissue. (b) TargetScan's predicted binding sites of miR-29b-3p and PDGF-B. (c) Luciferase Reporter testing results. These results are statistically analyzed using the Prism 6.0 software. Note that aP < 0.05 compared with the Sham group or the miR-29b-3p+MT group; bP < 0.05 compared with the Ang-II group.

• 

  Figure 2. MiR-29b-3p can inhibit PDGF-B expression. (a) RT-PCR detection results. (b, c) Western blotting testing and PDGF-B expression and quantitative analysis. (d, e) Immunohistochemical testing (×200, 100 μm) results and quantitative analysis. These results are statistically analyzed using the Prism 6.0 and Image-Pro 6.0 software. Note that aP < 0.05 compared with the Sham group; bP < 0.05 compared with the Ang-II group.

• 

  Figure 3. MiR-29b-3p can lower the degree of atrial fibrosis. (a) Overview observation of heart sample and Masson staining (×200, 100 μm) and analysis (b). These results are statistically analyzed using the Prism 6.0 and Image-Pro 6.0 software. Note that aP < 0.05 compared with the Sham group; bP < 0.05 compared with the Ang-II group.

• 

  Figure 4. MiR-29b-3p can reduce the expression level of fibrosis markers. (a) Immunofluorescence testing (×200, 100 μm) results: red light represents Collagen-I expression; blue light represents total myocardial nucleus (b) quantitative analysis. These results are statistically analyzed using the Prism 6.0 and Image-Pro 6.0 software. Note that aP < 0.05 compared with the Sham group; bP < 0.05 compared with the Ang-II group.

• 

  Figure 5. MiR-29b-3p can reduce the expression of fibrosis markers. (a) Western blotting testing and fibrosis marker expression and quantitative analysis (b, c). These results are statistically analyzed using the Prism 6.0 and Image-Pro 6.0 software. Note that aP < 0.05 compared with the Sham group; bP < 0.05 compared with the Ang-II group.

• 

  Figure 6. MiR-29b-3p can increase the expression of Cx43. (a, b) Western blotting testing and Cx43 expression and quantitative analysis. (c, d) Immunohistochemical testing (×200, 100 μm) results and quantitative analysis. These results are statistically analyzed using the Prism 6.0 and Image-Pro 6.0 software. Note that aP < 0.05 compared with the Sham group; bP < 0.05 compared with the Ang-II group.

• 

  Figure 7. The molecular mechanism diagram shows that miR-29b-3p may participate in the onset of atrial fibrillation by the PDGF-B signaling pathway to regulate atrial remodeling.